 strong quarter ingrezza orilissa
messag report strong rev/ep ahead consensu
takeaway ingrezza inhibitor approv tardiv dyskinesia sale
robust came well ahead consensu expect continu
robust growth despit manag attempt temper expect orilissa
gnrh antagonist launch track expect slower expect
uptak though l-t outlook maintain pdufa date
opicapon set april updat model better reflect
continu strong launch trajectori ingrezza reiter neutral share trade
hour increas pt
good quarter ingrezza expect continu robust growth though manag
tri temper expect
ingrezza sale came strong ingrezza sale came
y/i well ahead consensu estim
respect increment q/q script growth robust vs
season weak driven record number new patient
addit improv refil rate current across payor segment net
revenu per script increas impli lower gross-
to-net discount note even exclud inventori benefit
script q/q growth script significantli higher averag
six prior quarter excl season weak despit strong
number manag tri temper guidanc note q/q growth
respect season strong
season weak q/q growth respect therefor
compani expect continu increment new patient demand
increas overal prescript volum growth like temper
believ sale could conserv one assum net
increment prescript volum growth averag prior quarter
excl vs get increment q/q revenu increas
impli sale reflect current trend
also increas sale estim ingrezza peak sale estim
vs prior
orilissa uptak continu track expect guidanc lower l-t
guidanc maintain report previous orilissa sale came
vs impli consensu sale translat
royalti impli royalti rate management note
despit good coverag posit physician recept drug uptak continu slow
obgyn use prior-auth requir higher price drug women
typic go physician year less averag effort underway
increas frequenc offic visit therebi increas uptak base current trend
lower orilissa guid maintain long-term
outlook reflect current trend reduc royalti
revenu orilissa
opicapon pdufa date opicapon catechol-o-methyltransferas comt
inhibitor adjunct therapi levodopa/carbidopa patient parkinson
diseas experienc episod set april manag note
commerci infrastructur alreadi place product launch
page analyst certif import disclosur
orilissa elagolix nda treat uterin fibroid remain track
addit plan initi studi evalu elagolix polycyst ovari
receptor antagonist juli compani initi adapt
phase ii proof-of-concept studi evalu safeti pk/pd pediatr
patient classic meanwhil plan discuss program
adult patient fda third quarter
financi report total revenu q/q vs
consensu estim respect ingrezza sale
q/q vs consensu estim
respect orilissa royalti vs consensu estim
respect dilut ep came vs consensu
estim respect end cash
trend adjust
current
respect non-gaap ep
estim
respect base chang also increas npv-deriv
sum-of-th part sotp pt
expect
page analyst certif import disclosur
guggenheim secur llc research compani report
page analyst certif import disclosur
agentindicationtrialpotenti catalysttimingstock inhibitor tardiv dyskinesiaphas present re-kinect inhibitor parkinson diseasen/apdufa partner gnrh antagonist uterin fibroidsn/anda antagonist cahpivot phase adult initi trial pend fda voyag parkinson diseasephas idur diseasephas iitoplin dataest novel compoundmultipl disordersphas iiniti
guggenheim secur llc research compani report
pt increas nibx base sum-of-the-part sotp net-present-valu npv
includ probability-adjust npv ingrezza sale orilissa royalti opicapon sale technolog
valu compani anticip net cash posit
use discount rate termin valu believ appropri similar stage compani
upsid risk includ ingrezza and/or orilissa sale grow faster expect approv indic
downsid risk includ regulatori commerci setback potenti emerg new competitor
page analyst certif import disclosur
productsnpv mm probabl successnpv per cash outstand basic outstand fulli dilut includ share convert sum-of-th part sotp npv
page analyst certif import disclosur
licens incom expens incom tax rate incom cash flow capit rais compani report guggenheim secur llc estim mm yatin suneja
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc financi advisor inc strateg collabor inc
guggenheim secur llc affili expect receiv intend seek compens invest bank servic neurocrin
bioscienc inc abbvi inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
